NCT04794413View on ClinicalTrials.gov

Pimavanserin Treatment in TS

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Tourette SyndromeTardive Dyskinesia
Interventions
DRUG

Pimavanserin

Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
collaborator

Andrew Billnitzer, MD

UNKNOWN

lead

Joseph Jankovic

OTHER

NCT04794413 - Pimavanserin Treatment in TS | Biotech Hunter | Biotech Hunter